Comparison of morphine, oxycodone and the biased MOR agonist SR-17018 for tolerance and efficacy in mouse models of pain.

Comparison of morphine, oxycodone and the biased MOR agonist SR-17018 for tolerance and efficacy in mouse models of pain.
复制标题

吗啡、羟考酮和偏向性莫尔激动剂SR-17018在小鼠疼痛模型中的耐受性和功效的比较。

DOI:
10.1016/j.neuropharm.2020.108439
复制
发表时间:
2021-03-01
期刊:
影响因子:
4.7
通讯作者:
Bohn LM
Bohn LM
中科院分区:
医学2区
文献类型:
--
作者:
Pantouli F;Grim TW;Schmid CL;Acevedo-Canabal A;Kennedy NM;Cameron MD;Bannister TD;Bohn LM

文献摘要

参考文献

被引文献

相似文献

在细胞实验中,mu阿片受体选择性激动剂SR-17018优先激活gtp - γ -s结合,而不是βarrestin2募集,从而显示信号偏导。在小鼠中,SR-17018刺激gtp - γ - s在脑干的结合,产生类似吗啡的抗痛觉作用。然而,在热板实验中,重复给药后,它产生的呼吸抑制要小得多,小鼠也不会产生抗伤性耐受性。在此,我们评估了急性和重复给药SR-17018、羟考酮和吗啡对其他疼痛相关行为模型的影响。在小鼠温水尾浸泡实验中,评估脊髓对热痛觉的反射,重复给药SR-17018产生耐受性,吗啡和羟考酮也产生耐受性。SR-17018在福尔马林诱导的炎症性疼痛模型中反复给药后仍然有效,而羟考酮则没有。在化疗诱导的神经病变疼痛模型中,SR-17018比吗啡或羟考酮更有效,而且,这种疗效在重复给药SR-17018后仍保持不变。这些发现表明,除了甩尾试验外,SR-17018在多种疼痛模型的慢性治疗中仍然有效。
The mu opioid receptor-selective agonist, SR-17018, preferentially activates GTPγS binding over βarrestin2 recruitment in cellular assays, thereby demonstrating signaling bias. In mice, SR-17018 stimulates GTPγS binding in brainstem and produces antinociception with potencies similar to morphine. However, it produces much less respiratory suppression and mice do not develop antinociceptive tolerance in the hot plate assay upon repeated dosing. Herein we evaluate the effects of acute and repeated dosing of SR-17018, oxycodone and morphine in additional models of pain-related behaviors. In the mouse warm water tail immersion assay, an assessment of spinal reflex to thermal nociception, repeated administration of SR-17018 produces tolerance as does morphine and oxycodone. SR-17018 retains efficacy in a formalin-induced inflammatory pain model upon repeated dosing, while oxycodone does not. In a chemotherapeutic-induced neuropathy pain model SR-17018 is more potent and efficacious than morphine or oxycodone, moreover, this efficacy is retained upon repeated dosing of SR-17018. These findings demonstrate that, with the exception of the tail flick test, SR-17018 retains efficacy upon chronic treatment across several pain models.
DOI: 10.1016/0006-291x(90)91544-3
发表时间: 1990-11-15
影响因子: 3.1
作者:
HERBERT, JM;AUGEREAU, JM;MAFFRAND, JP
通讯作者: MAFFRAND, JP
DOI: 10.1111/j.1476-5381.1981.tb10473.x
发表时间: 1981-01-01
影响因子: 7.3
作者:
DUM, JE;HERZ, A
通讯作者: HERZ, A
DOI: 10.3109/00207454.2014.896913
发表时间: 2015-01-01
影响因子: 2.2
作者:
Bu, Huilian;Liu, Xijiang;Gao, Feng
通讯作者: Gao, Feng
DOI: 10.1038/tp.2014.121
发表时间: 2014-11-11
影响因子: 6.8
作者:
Johnson JL;Rolan PE;Johnson ME;Bobrovskaya L;Williams DB;Johnson K;Tuke J;Hutchinson MR
通讯作者: Hutchinson MR
DOI: 10.1126/science.286.5449.2495
发表时间: 1999-12-24
期刊: SCIENCE
影响因子: 56.9
作者:
Bohn, LM;Lefkowitz, RJ;Lin, FT
通讯作者: Lin, FT